U.S.-based pharmaceutical giant Pfizer and German biotech company BioNTech were already collaborating to come up with a flu vaccine based on a genetic material called mRNA. When COVID-19 emerged, they quickly agreed to partner to test candidates developed by BioNTech that, just under a year later, led to the first COVID-19 vaccine authorized for emergency use by the U.S. FDA. Pfizer’s experience in conducting clinical trials demonstrated, in record time, that the companies’ vaccine was 95% efficacious in protecting people from COVID-19—which was confirmed in real-world studies involving millions of vaccinated people—and its scale will help produce an expected 2.5 billion doses in 2021.
Correction, April 29
This story’s original photo caption misstated Türeci and Sahin’s location. They were in Mainz, Germany; not at a production facility in Marburg, Germany.
- Introducing the 2024 TIME100 Next
- Sabrina Carpenter Has Waited Her Whole Life for This
- What Lies Ahead for the Middle East
- Why It's So Hard to Quit Vaping
- Jeremy Strong on Taking a Risk With a New Film About Trump
- Our Guide to Voting in the 2024 Election
- The 10 Races That Will Determine Control of the Senate
- Column: How My Shame Became My Strength
